Month: April 2020

BCR/ABL Gene Expression Assay on the Combinati Absolute Q

95% of Chronic Myeloid Leukemia (CML) cases are characterized by the presence of a BCR-ABL1 fusion gene. Regular monitoring involving precise quantification of BCR-ABL1 transcripts is integral to successful tyrosine kinase inhibitor (TKI) treatment. Read more about how samples with precise ratios of BCR-ABL1/ABL1 were created and confirmed on the Combinati dPCR platform.